RSS Nyheter

Bioglan has entered a collaboration project with Malmö University

Fri, 04 May 2012 11:14:00 +0200

Bioglan will through the participation in this project strengthen their knowledge base in the nasal drug delivery field and thereby create a good base for new development projects. The Biofilms-Research Center for Biointerfaces, which is the participant from Malmö University, has a profile that promotes good relations with partner industry. “Research collaboration with industry is very valuable for us, says Johan Engblom, Associate professor at Malmö University, and manager for the current project. It provides a balance between academic research and market needs. It also motivates our students and gives them a good insight in how development projects are run in the industry.” The project will run until the end of 2013. For further information regadring the project please contact Torbjörn Sund, torbjorn.sund@bioglan.se, +46 40 287520

Gör ditt examensarbete (Diploma work) på Bioglan!

Wed, 16 Nov 2011 00:00:00 +0100

A system for stabilizing emulsions has been developed at the division of Food Technology, Lund University. A potential use for these types of emulsions is in topical creams for both cosmetic use and as a drug delivery formulation / medical device. The specific project aim is to further develop the composition of the model cream to obtain one or few relevant test products for further trials. The project will be performed together SPEximO and Bioglan.

För mer information kontakta utvecklingschef Birgitta Svensson.

Tfn: 040-287561, E-post: birgitta.svensson@bioglan.se

Bioglan at ICSE, Frankfurt 25-27 October

Mon, 19 Sep 2011 12:05:00 +0200

You can use this invitation to book a meeting with a member of our expert team to discuss an upcoming project find out what’s new at Bioglan find out what’s new at RJ Group discover how we can develop your business Send an e-mail to birgitta.svensson@bioglan.se or totte.malmstrom@bioglan.se and suggest a date and time for a meeting and we will get back to you. Visit us at Stand 41D40

BLOX4™ Allergy

Wed, 06 Apr 2011 09:22:00 +0200

BLOX4™ Allergy is a new product launched in Sweden in April 2011. BLOX4™ Allergy efficiently blocks allergens from reaching the nasal mucosa and releasing the histamine cascade. Read more and find your nearest pharmacy at: www.BLOX4Allergy.se

Poster presentation at AAD 2011

Thu, 27 Jan 2011 00:00:00 +0100

Abstract to Poster 3700 Hydrogen peroxide, H₂O₂, solution 1-6% has been used for cleaning of wounds for many years but is not recommended nowadays due to its concern about potential tissue damaging effects. The product studied here is a H₂O₂cream which has been on the market for many years for treatment and prevention of minor skin infections. The H₂O₂is stabilised through embedding in a lipid crystalline structure resulting in a depot cream. The lipids used boost the antimicrobial effect of the hydrogen peroxide and the sustained release system results in a product with long lasting antimicrobial effect in situ. The cream is an excellent alternative to topical antibiotics without the risk for bacterial resistance which is an increasing concern. An increased clinical effect has been observed for wound healing when using this cream and this effect is more than an antimicrobial cleaning effect. The exact role and therapeutic levels of H₂O₂is not completely understood even if recent knowhow of H₂O₂as part of the signalling messenger in wound healing is available. The studies presented here are aiming to correlate the concentration of endogeneous H₂O₂at the wound site and the significance of exogenous hydrogen peroxide in wound healing. H₂O₂is in the body a naturally occurring mediator which is released in inflammatory processes. It could positively affect wound healing by increasing angiogenesis, facilitate fibroblast proliferation and activity, and increase wound constriction. At the same time excessive H₂O₂may be toxic and prevent wound healing. Release of H₂O₂from various formulations including 1% solution and cream, 0.5% solution and cream, and 0.25% cream through flow cells over a period of four hours using dialysis membranes was determined. The release of H₂O₂was proportional to the concentration in the donor formulations. The concentration released to the wound surface was correlated to bridging cell proliferation studies using cultures of L929 mouse fibroblast and MTS-assay for 24 h and 48 h, respectively. The concentrations of H₂O₂ranged from 10^-3 to 10^-10 M, where 10^-3 M and 10^-5 M H₂O₂had a profound antiproliferative effect on the L929 cells, compared to the control without addition of H₂O₂. Whether H₂O₂ at the concentrations 10^-6 to 10^-10 M are beneficial for cell proliferation or not, is currently investigated. In conclusion, there is a steady release rate of H₂O₂over the dialysis membrane, and H₂O₂can inhibit L929 cell proliferation at high concentrations.

Bioglan is SS-EN ISO 13485:2003 certified

Fri, 01 Oct 2010 14:43:00 +0200

Bioglan’s quality systems now works both according to GMP and ISO13485. The extension with ISO13485 means that it will be easier for companies that need our help to either develop, manufacture or market medical devices to the EU market. Since Bioglan also covers pharmaceuticals in its ISO certificate, the development and manufacture of these products will be even more efficient and with the quality required.

Bioglan at ICSE/CPhI in Paris 5th – 7th October 2010

Fri, 17 Sep 2010 12:47:00 +0200

Please visit us at ICSE/CPhI in Paris 5th – 7th October 2010 Reig Jofré Group Booth No. 4F86, Hall 4 – ICSE area CDMOs in southern Sweden Booth No. 4J83, Hall 4 - ICSE area You can use this invitation to book a meeting with a member of our expert team to

discuss an upcoming project need
discuss an upcoming product manufacturing need
find out what’s new at Bioglan
find out what’s new at RJ Group
discover how Bioglan can develop your business

Send an e-mail to birgitta.svensson@bioglan.se or totte.malmstrom@bioglan.se and suggest a date and time for a meeting and we will get back to you.

Simon Björklund, PhD, Nordic Business Development Manager

Tue, 17 Aug 2010 15:13:00 +0200

Simon previously worked with business development at a temporary staffing and recruitment company, where the focus was on the Life Science sector and the deregulation of the Swedish pharmacy market. Earlier in his career, Simon has covered the areas of biotechnology and environmental research, B2C sales and teaching. Simon started at Bioglan AB on August 2^nd. –“I am very excited to start at Bioglan AB, where my interest and experience in Life Science and Business are combined perfectly, says Simon”.

MA holder for Scandinavia

Wed, 24 Mar 2010 13:37:00 +0100

The assets of Bioglan AB were as of September 1^st 2009 acquired by the Spanish family-owned group Reig Jofré. The final part of the deal was the transfer of the market authorisation (MA) of nine products for the Scandinavian market. This part of the deal was due March 1^st 2010. All nine product will in the future be supplied by Bioglan AB on the Scandinavian market. Three of the products, Micanol, Crystacide and LHP, are developed and manufactured by Bioglan AB (the product Crystacide is in Sweden known under the trademark Microcid). The remaining products are known under the trademarks Amosyt, Capsina, Hibitane, Metosyn, Synalar and Tenutex. Some of these products are also manufactured by Bioglan AB today. For further information please contact: Totte Malmström, CEO, Bioglan AB, tel +46 40 287575 (office) / +46 70 725 725 8 (mobile) www.bioglan.se

Bioglan at BioSquare Geneva 2010

Tue, 12 Jan 2010 00:00:00 +0100

The main objective for taking part of BioSquare is to make our contract development and manufacturing organisation available to other organisations, which require this type of service. We offer all services you require within the field of semi-solids and liquids. New products are continuously developed within the Reig Jofré Group and we also look for partners for these products all over the world. Two products registered as medical device are within short offered for out-licensing.

The product, presently called Zalve, is designed to facilitate healing and prevent the growth of microorganisms in small wounds. This product can be used as a first aid cream and is an alternative treatment to topical antibiotics.
The product, presently called Ameliorin, is a microemulsion which prevents and alleviates perennial rhinitis allergy where symptoms are caused by pollen, dust mite, animal fur and other allergens by forming a protective barrier in the nasal cavity.

Please contact us for a meeting on the official home page of BioSquare: www.biosquare.com